PL84212B1 - - Google Patents
Download PDFInfo
- Publication number
- PL84212B1 PL84212B1 PL1971174903A PL17490371A PL84212B1 PL 84212 B1 PL84212 B1 PL 84212B1 PL 1971174903 A PL1971174903 A PL 1971174903A PL 17490371 A PL17490371 A PL 17490371A PL 84212 B1 PL84212 B1 PL 84212B1
- Authority
- PL
- Poland
- Prior art keywords
- group
- carbon atoms
- formula
- hydroxy
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- -1 1,1-dimethyl--2-hydroxyethyl Chemical group 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- MFKJRCZRAWTCHS-UHFFFAOYSA-N 2-(1-amino-2,5-dihydroxy-4,4-dimethylpentoxy)benzonitrile Chemical compound C(#N)C1=C(OC(C(CC(CO)(C)C)O)N)C=CC=C1 MFKJRCZRAWTCHS-UHFFFAOYSA-N 0.000 description 1
- YIUIVFFUEVPRIU-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21 YIUIVFFUEVPRIU-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- FQYUMYWMJTYZTK-UHFFFAOYSA-N Phenyl glycidyl ether Chemical compound C1OC1COC1=CC=CC=C1 FQYUMYWMJTYZTK-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Description
Przedmiotem wynalazku jest sposób wytwarza¬ nia nowych l-fenoksy-2-hydroksy-3-hydroksyalki- loaminopropanów, ich estrów i soli addycyjnych z kwasami. Nowe zwiazki moga wystepowac w postaci racematów i optycznych antypodów.Nowym zwiazkom odpowiada wzór ogólny 1, w którym Hal oznacza chlorowiec, Ri oznacza gru¬ pe o wzorze (CH2)X—CN, (CH2)X—NH2 lub (CH2)x+i—OH (przy czym x oznacza liczbe calko¬ wita 0—3), grupe o wzorze —COOR5 (przy czym R5 oznacza wodór lub grupe alkilowa o 1—4 ato¬ mach wegla), grupe alkenylowa, alkenyloksylowa, alkinylowa lub alkinyloksylowa o 2—5 atomach wegla, R2 oznacza wodór, chlorowiec lub grupe alkilowa lub alkosylowa o 1—4 atomach wegla i R3 oznacza prosta lub rozgaleziona grupe hydro- ksyalkilowa o 3—6 atomach wegla.Wedlug wynalazku nowe zwiazki wytwarza sie przez chlorowcowanie zwiazku o wzorze ogólnym 2, w którym Ri—R2 maja wyzej podane znacze¬ nie.Chlorowcowanie prowadzi sie np. przez reakcje zwiazku o wzorze 2 z mieszanina stezonego nad¬ tlenku wodoru i odpowiedniego kwasu chlorow- cowodorowego w podwyzszonej temperaturze, jed¬ nakze tylko wtedy, gdy pozostala czesc czasteczki nie zawiera grupy zdolnej do zmienienia sie pod dzialaniem tego srodka.Zwiazki o wzorze 2 zawieraja juz gotowy szkie¬ let l-fenoksy-2-hydroksy-3-hydroksyalkiloamino- propanu i mozna je wytwarzac przeto przez reak¬ cje odpowiedniego fenolu z epichlorohydryna i na¬ stepnie reakcje otrzymanego l-fenoksy-2,3-epoksy- propanu z hydroksyalkiloamina.Otrzymywane sposobem wedlug wynalazku zwiazki posiadaja asymetryczny atom wegla w grupie CHOH i moga wskutek tego wystepowac zarówno w postaci racematu, jak i optycznych antypodów. Te ostatnie mozna otrzymywac przez rozdzielenie racematu za pomoca znanych kwa¬ sów pomocniczych, takich jak kwas dwubenzoilo- (wzglednie dwu-p-toluilo-)D-winowy lub kwas D-3-bromokamforo-8-sulfonowy oraz przez stoso¬ wanie optycznie czynnych zwiazków wyjsciowych.Otrzymywane sposobem wedlug wynalazku 1-fe- noksy-2-hydroksy-3-hydroksyalkiloaminopropany o wzorze ogólnym 1 mozna w znany sposób przepro¬ wadzic w ich fizjologicznie dopuszczalne sole ad¬ dycyjne z kwasami. Odpowiednimi kwasami sa np. kwas solny, bromowodorowy, siarkowy, meta- nosulfonowy, maleinowy, octowy, szczawiowy, mle¬ kowy, winowy lub 8-chloroteofilina. Równiez w znany sposób mozna zwiazki te przeprowadzic w estry, np. przez reakcje z halogenkami lub bez- wodwnikami acylowymi. Najuzyteciziniejszymi estra¬ mi sa np. 2-octany wzglednie 2-propioniany.Zwiazki o wzorze ogólnym 1 wzglednie ich fi¬ zjologicznie dopuszczalne sole addycyjne z kwa¬ sami wykazuja w badaniach na swinkach mor- skich wartosciowe wlasciwosci terapeutyczne, w 842123 szczególnosci dzialanie jff-adrenolityczne i mozna je wskutek tego stosowac np. do leczenia i pro¬ filaktyki schorzen naczyn wiencowych serca i aryt- mii serca, w szczególnosci tachycardii, w medy¬ cynie. Równiez dzialanie obnizajace cisnienie krwi powoduje, ze zwiazki te sa pod wzgledem tera¬ peutycznym interesujace. Zwiazki te, w porów¬ naniu ze znanymi zwiazkami blokujacymi ^-recep¬ tory np. wobec l-(;nadfyloksy)-2hydroksy-3-izo- propyloaminopropanu (propranololu), sa znacznie mniej toksyczne.Szczególnie wartosciowymi okazaly sie zwiazki o wzorze 1, w którym R4 oznacza rozgaleziona grupe hydroksyalkilowa, zwlaszcza 1,1-dwumetylo- -2-hydroksyetylowa.Dawka jednostkowa zwiazków otrzymywanych sposobem wedlug wynalazku wynosi 1—300 mg, zwja^zc^a, 5-^00 *mg (doustnie), wzglednie 1—20 mg (pozajelit owo).*¦<-¦* "Nowe substancje czynne mozna przeprowadzic w znane galenowe formy uzytkowe, jak tabletki, drazetki, roztwory, emulsje, proszki, kapsulki oraz preparaty o przedluzonym dzialaniu, przy czym do wytwarzania ich stosuje sie znane farmaceu¬ tyczne srodki pomocnicze oraz znane sposoby spo¬ rzadzania ich. Tabletki wytwarza sie np. przez zmieszanie substancji czynnej ze znanymi srodka¬ mi pomocniczymi np. obojetnymi rozcienczalnika¬ mi, jak weglan wapnia, fosforan wapnia lub cu¬ kier mlekowy, srodkami rozkruszajacymi, jak skro¬ bia kukurydziana lub kwas alginowy, srodkami wiazacymi, jak skrobia lub zelatyna, srodkami poslizgowymi, jak stearynian magnezu lub talk iAub srodkami powodujacymi osiagniecie przedlu¬ zonego dzialania, jak karboksypolimetylen, karbo- ksymetyloceluloza, ftalan acetylocelulozowy lub po¬ lioctan winylu.Tabletki moga byc wielowarstwowe. Drazetki otrzymuje sie przez powlekanie rdzeni, wytwo¬ rzonych analogicznie jak tabletki, w znany spo¬ sób, stosowanymi do powlok drazetek srodkami, takimi jak np. kolidon lub szelak, guma arabska, talk, dwutlenek tytanu lub cukier. W celu osiag¬ niecia przedluzonego dzialania oraz unikniecia nie¬ zgodnosci, rdzen moze byc równiez wielowarstwo¬ wy, podobnie jak sporzadza sie w tym samym ce¬ lu wielowarstwowe powloki, przy czym stosuje wspomniane wyzej przy tabletkach srodki pomoc¬ nicze.Eliksiry z subtancja czynna lub polaczeniem sub¬ stancji czynnych moga zawierac dodatkowo srod¬ ki slodzace, jak sacharyna, cyklaminian, gliceryna lub cukier oraz substancje polepszajace smak np. substancje aromatyzujace, jak wanilina lub eks¬ trakt pomaranczowy. Ponadto moga one zawierac pomocnicze srodki zawieszajace lub zageszczajace, jak sól sodowa karboksymetylocelulozy srodki zwil¬ zajace, np. produkty kondensacji alkoholi tluszczo¬ wych z tlenkiem etylenu lub srodki konserwujace, jak p-hydroksybenzoesan.Roztwory injekcyjne wytwarza sie w znany spo¬ sób, np. z dodatkiem srodka konserwujacego, jak p-hydroksybenzoesan lub stabilizatorów, jak kom- pleksony. Roztworami takimi napelnia sie fiolki injekcyjne lub ampulki. 4 Kapsulki z subtancja czynna lub z polaczeniem substancji czynnych, wytwarza sie, np. przez zmieszanie substancji czynnej z obojetnymi nosni¬ kami, takimi jak cukier mlekowy lub sorbit. Mie- szanina ta napelnia sie kapsulki z zelatyny i za¬ myka.Czopki wytwarza sie np. przez zmieszanie sub¬ stancji czynnej lub substancji czynnych ze zna¬ nymi nosnikami, takimi jak tluszcze obojetne lub poliglikol etylenowy ewentualnie jego pochodne.Zwiazki otrzymywane sposobem wedlug wyna¬ lazku mozna laczyc z innymi farmakodynamicz- nie czynnymi substancjami, takimi jak np. sub¬ stancje rozszerzajace naczynia wiencowe, pobu¬ dzajace uklad wspólczulny, glikozydy nasercowe lub srodki uspokajajace.Nastepujace przyklady wyjasniaja blizej wyna¬ lazek, nie ograniczajac jego zakresu.Przyklad L l-(2-cyjano-4-chlorofenoksy)-2-hy- droksy-3-(l,l-dwumetylo-2-hydroksyetylo)-amino- propan. propan. 9,7 g (okolo 0,037 mola) i l-(2-cyjanofeno- ksy)-2-hydroksy-3-(l,l-dwumetylo-2-hydroksyetylo)- -aminopropanu rozpuszcza sie w 75 ml stezonego HC1 i ogrzewa do temperatury 45°C. Nastepnie wkrapla sie 4,17 g (okolo 0,038 mola) 30% roztwo¬ ru H2O2. Reakcja jest silnie egzotermiczna. Utrzy¬ muje sie przez oziebianie temperature 65°C. Tem- 81 perature 60—65°C utrzymuje sie podczas miesza¬ nia, przez 0,5 godziny. Nastepnie odparowuje sie w prózni do sucha. Pozostalosc rozpuszcza sie - w wodzie, wytrzasa 2 razy z eterem i alkalizuje 2n NaOH. Wydzielony olej rozpuszcza sie w eterze.Bo przemyciu wyisuiszeniu i odipairowamiiu elteru po¬ zostalosc wynosi 9,3 g. W celu oczyszczenia sub¬ stancje przekrystalizowuje sie 2 razy z octanu ety¬ lu z dodatkiem eteru naftowego (temperatura wrzenia 40—60°Q. Wydajnosc: 6,6 g, temperatu- 40 ra topnienia: 102—103°C (zasada).Przyklad II. l-(2-cyjano-4-chlorofenoksy)-2- -hydroksy-3-(l-metylo-2-hydroksyetylo)-aminopro- pan. Chlorowanie l-(2-cyjanofenoksy)-2-hydroksy- 45 -3-(-metylo-2-hydroksyetylo)-aminopropanu prowa¬ dzi sie analogicznie, jak w przykladzie I.Przez frakcjonowana krystalizacje otrzymuje sie dwie formy stereoizomeryczne, topniejace w tem¬ peraturze 141—143°C wzglednie 113^114°C. .» • R1 /~^-~OCH2~CHOH-CH2-NH-R3 Harn" Ro Wzór 1 R1 {TV 0CH2" CH0H-CH2-NHR3 R2 Wzór 2 DN z-3, zam. 2541/76 Cena 10 zl PL PL PL PL PL PL
Claims (1)
1. Zastrzezenie patentowe Sposób wytwarzania nowych l-fenoksy-2-hydro- 55 ksy-3-hydroksyalkiloaminopropanów, o wzorze ogól¬ nym 1, w którym Hal oznacza chlorowiec, Ri oznacza grupe o wzorach (CH2)X—CN, (CH2)X—NH2 lub (CH2)x+i—OH, przy czym x ocnaciza liczbe cal¬ kowita 0—3, grupe o wzorze —COOR5, w którym 60 R5 oznacza wodór lub grupe o 1—4 atomach we¬ gla, grupe alkenylowa, alkinylowa, alkenyloksylo- wa lub alkinyloksylowa o 2—5 atomach wegla, R2 oznacza wodór, chlorowiec lub grupe alkilowa lub alkoksylowa o 1—4 atomach wegla, R3 ozna- 65 cza prosta lub rozgaleziona grupe hydroksyalkilo-84212 5 6 wa o 3—6 atomach wegla, w postaci racematów waniu, otrzymany racemat ewentualnie rozszcze- i optycznych antypodów znamienny tym, ze zwia- pia sie na optyczne antypody i/lub otrzymany zek o ogólnym wzorze 2, w którym Ri—R3 ma- zwiazek o wzorze 1 przeprowadza w sól addy- ja wyzej podane znaczenie, poddaje sie chlorowco- cyjna z kwasem lub w ester.84212 *. *"n—¦ • •• • •• PL PL PL PL PL PL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19702048838 DE2048838A1 (de) | 1970-10-05 | 1970-10-05 | Neue 1 Phenoxy 2 hydroxy 3 hydroxyal kylaminopropane und Verfahren zu ihrer Her stellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL84212B1 true PL84212B1 (pl) | 1976-03-31 |
Family
ID=5784228
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971174905A PL84226B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174907A PL84224B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174908A PL84223B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174912A PL84276B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971150902A PL82037B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174906A PL84225B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174909A PL84267B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174910A PL84396B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174903A PL84212B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174911A PL84227B1 (pl) | 1970-10-05 | 1971-10-04 |
Family Applications Before (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971174905A PL84226B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174907A PL84224B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174908A PL84223B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174912A PL84276B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971150902A PL82037B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174906A PL84225B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174909A PL84267B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174910A PL84396B1 (pl) | 1970-10-05 | 1971-10-04 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971174911A PL84227B1 (pl) | 1970-10-05 | 1971-10-04 |
Country Status (26)
| Country | Link |
|---|---|
| JP (1) | JPS5710097B1 (pl) |
| AT (10) | AT318569B (pl) |
| AU (1) | AU469119B2 (pl) |
| BE (1) | BE773472A (pl) |
| BG (8) | BG20100A3 (pl) |
| CA (1) | CA1008866A (pl) |
| CH (11) | CH564507A5 (pl) |
| CS (2) | CS172932B2 (pl) |
| DE (1) | DE2048838A1 (pl) |
| DK (1) | DK130958B (pl) |
| ES (8) | ES395671A1 (pl) |
| FI (1) | FI55491C (pl) |
| FR (1) | FR2110230B1 (pl) |
| GB (1) | GB1364280A (pl) |
| HU (1) | HU163226B (pl) |
| IE (1) | IE35693B1 (pl) |
| IL (1) | IL37830A (pl) |
| NL (1) | NL174249C (pl) |
| NO (1) | NO132835C (pl) |
| PH (1) | PH9959A (pl) |
| PL (10) | PL84226B1 (pl) |
| RO (8) | RO61540A (pl) |
| SE (1) | SE383631B (pl) |
| SU (2) | SU419024A3 (pl) |
| YU (2) | YU35576B (pl) |
| ZA (1) | ZA716643B (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4055658A (en) * | 1976-05-17 | 1977-10-25 | Mead Johnson & Company | Cyanomethylphenethanolamines |
| DE3248835A1 (de) * | 1981-06-23 | 1983-06-30 | American Hospital Supply Corp | Zusammensetzungen fuer die behandlung von glaukom |
| US4454154A (en) * | 1981-06-23 | 1984-06-12 | American Hospital Supply Corporation | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
| US4652584A (en) * | 1984-07-13 | 1987-03-24 | Mcneilab, Inc. | Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension |
| DE4422707A1 (de) | 1994-06-29 | 1996-01-04 | Hoechst Ag | Verfahren zum Färben aminierter Cellulose-/Polyester-Mischgewebe mit faserreaktiven Dispersionsfarbstoffen |
| JP4934287B2 (ja) * | 2005-04-05 | 2012-05-16 | 花王株式会社 | 美白剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD45360A (pl) * | ||||
| CA945172A (en) * | 1969-02-21 | 1974-04-09 | Imperial Chemical Industries Limited | Alkanolamine derivatives |
-
1970
- 1970-10-05 DE DE19702048838 patent/DE2048838A1/de not_active Withdrawn
-
1971
- 1971-04-10 SE SE7112536*A patent/SE383631B/xx unknown
- 1971-09-30 SU SU1700834A patent/SU419024A3/ru active
- 1971-10-01 CH CH1430971A patent/CH564507A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424675A patent/CH564516A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424375A patent/CH563341A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424275A patent/CH583687A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH423975A patent/CH583685A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424075A patent/CH583686A5/xx not_active IP Right Cessation
- 1971-10-01 IL IL37830A patent/IL37830A/xx unknown
- 1971-10-01 CH CH424175A patent/CH584185A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424575A patent/CH563342A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH423875A patent/CH587223A5/xx not_active IP Right Cessation
- 1971-10-04 NO NO3632/71A patent/NO132835C/no unknown
- 1971-10-04 BG BG020287A patent/BG20100A3/xx unknown
- 1971-10-04 GB GB4610371A patent/GB1364280A/en not_active Expired
- 1971-10-04 JP JP7778571A patent/JPS5710097B1/ja active Pending
- 1971-10-04 DK DK481671AA patent/DK130958B/da not_active IP Right Cessation
- 1971-10-04 PL PL1971174905A patent/PL84226B1/pl unknown
- 1971-10-04 CA CA124,290A patent/CA1008866A/en not_active Expired
- 1971-10-04 PL PL1971174907A patent/PL84224B1/pl unknown
- 1971-10-04 PL PL1971174908A patent/PL84223B1/pl unknown
- 1971-10-04 BG BG020291A patent/BG18859A3/xx unknown
- 1971-10-04 BG BG020286A patent/BG18857A3/xx unknown
- 1971-10-04 PL PL1971174912A patent/PL84276B1/pl unknown
- 1971-10-04 YU YU2505/71A patent/YU35576B/xx unknown
- 1971-10-04 FI FI2769/71A patent/FI55491C/fi active
- 1971-10-04 PL PL1971150902A patent/PL82037B1/pl unknown
- 1971-10-04 BG BG20289A patent/BG19134A3/xx unknown
- 1971-10-04 PL PL1971174906A patent/PL84225B1/pl unknown
- 1971-10-04 BG BG020285A patent/BG19133A3/xx unknown
- 1971-10-04 PH PH12895A patent/PH9959A/en unknown
- 1971-10-04 PL PL1971174909A patent/PL84267B1/pl unknown
- 1971-10-04 PL PL1971174910A patent/PL84396B1/pl unknown
- 1971-10-04 BE BE773472A patent/BE773472A/xx not_active IP Right Cessation
- 1971-10-04 BG BG018670A patent/BG20338A3/xx unknown
- 1971-10-04 PL PL1971174903A patent/PL84212B1/pl unknown
- 1971-10-04 BG BG020288A patent/BG18858A3/xx unknown
- 1971-10-04 BG BG020290A patent/BG19793A3/xx unknown
- 1971-10-04 ES ES395671A patent/ES395671A1/es not_active Expired
- 1971-10-04 PL PL1971174911A patent/PL84227B1/pl unknown
- 1971-10-04 ZA ZA716643A patent/ZA716643B/xx unknown
- 1971-10-04 NL NLAANVRAGE7113581,A patent/NL174249C/xx not_active IP Right Cessation
- 1971-10-05 IE IE1246/71A patent/IE35693B1/xx unknown
- 1971-10-05 AU AU34182/71A patent/AU469119B2/en not_active Expired
- 1971-10-05 RO RO68372A patent/RO61540A/ro unknown
- 1971-10-05 AT AT735273A patent/AT318569B/de not_active IP Right Cessation
- 1971-10-05 AT AT735373A patent/AT318570B/de not_active IP Right Cessation
- 1971-10-05 AT AT735073A patent/AT318567B/de not_active IP Right Cessation
- 1971-10-05 AT AT734773A patent/AT318564B/de not_active IP Right Cessation
- 1971-10-05 AT AT734973A patent/AT318566B/de not_active IP Right Cessation
- 1971-10-05 CS CS7034A patent/CS172932B2/cs unknown
- 1971-10-05 FR FR7135823A patent/FR2110230B1/fr not_active Expired
- 1971-10-05 AT AT735573A patent/AT318572B/de not_active IP Right Cessation
- 1971-10-05 RO RO7100073338A patent/RO62358A/ro unknown
- 1971-10-05 RO RO7100073333A patent/RO62355A/ro unknown
- 1971-10-05 AT AT735473A patent/AT318571B/de not_active IP Right Cessation
- 1971-10-05 RO RO7100073337A patent/RO62267A/ro unknown
- 1971-10-05 RO RO73334A patent/RO62356A/ro unknown
- 1971-10-05 HU HUBO1319A patent/HU163226B/hu unknown
- 1971-10-05 RO RO73336A patent/RO62313A/ro unknown
- 1971-10-05 RO RO7100073339A patent/RO62359A/ro unknown
- 1971-10-05 AT AT734873A patent/AT318565B/de not_active IP Right Cessation
- 1971-10-05 AT AT735173A patent/AT318568B/de not_active IP Right Cessation
- 1971-10-05 CS CS4618A patent/CS172950B2/cs unknown
- 1971-10-05 RO RO7100073335A patent/RO62357A/ro unknown
- 1971-10-05 AT AT859371A patent/AT318561B/de not_active IP Right Cessation
-
1972
- 1972-02-17 ES ES399869A patent/ES399869A1/es not_active Expired
- 1972-02-17 ES ES399873A patent/ES399873A1/es not_active Expired
- 1972-02-17 ES ES399871A patent/ES399871A1/es not_active Expired
- 1972-02-17 ES ES399868A patent/ES399868A1/es not_active Expired
- 1972-02-17 ES ES399870A patent/ES399870A1/es not_active Expired
- 1972-02-17 ES ES399874A patent/ES399874A1/es not_active Expired
- 1972-02-17 ES ES399872A patent/ES399872A1/es not_active Expired
-
1973
- 1973-02-28 SU SU731888527A patent/SU677649A3/ru active
-
1975
- 1975-04-03 CH CH414475A patent/CH564515A5/xx not_active IP Right Cessation
-
1976
- 1976-12-06 CH CH1430971A patent/CH587227A5/xx not_active IP Right Cessation
-
1979
- 1979-02-02 YU YU236/79A patent/YU35577B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4689341A (en) | Antiarrhythmic imidazoles | |
| PL93499B1 (pl) | ||
| CN1894231B (zh) | 作为ep4受体拮抗剂的呋喃衍生物 | |
| CS236679B2 (en) | Manufacturing process of new benzoheterocyclic compounds | |
| JPS6230780A (ja) | 1,7−ナフチリジン誘導体及びこれを含有する薬剤 | |
| JPS62255474A (ja) | 抗不整脈剤 | |
| US4460605A (en) | 2-[2'-Hydroxy-3'-(1,1-dimethylpropylamino)-propoxy]-β-phenylpropiophenone, its physiologically acceptable acid addition salts, and pharmaceutical compositions | |
| PL84212B1 (pl) | ||
| PL90039B1 (pl) | ||
| EP0003664B1 (en) | Alkanolamine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| RU2161613C2 (ru) | Арилалкилтиадиазиноны, способ их получения, фармацевтическая композиция | |
| PL84520B1 (en) | 1-(2'-cyano-phenoxy)-2-hydroxy-3-ethylamino-propane and salts thereof[us3732277a] | |
| DE2719562A1 (de) | 3, 4-dihydrocarbostyrilderivate und verfahren zu deren herstellung | |
| EP0011747B1 (de) | Aminopropanolderivate des 6-Hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-2-ons, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| CZ281377B6 (cs) | Thiadiazinony, způsob jejich výroby a farmaceutické přípravky na jejich bázi | |
| EP0038936B1 (de) | Neue 1-Aryloxy-3-alkylamino-2-propanole und Verfahren zu ihrer Herstellung | |
| US4613609A (en) | Antiarrhythmic imidazoliums | |
| PL96042B1 (pl) | Sposob wytwarzania nowych aminopochodnych azydofenoli | |
| HU186488B (en) | Process for producing pyridine derivatives and pharmaceutival compositions containing them as active agents | |
| EP0073016B1 (de) | Neue 1-Aryloxy-3-alkylamino-2-propanole und Verfahren zu ihrer Herstellung | |
| JPS58152872A (ja) | オキサゾリジン−2−オン化合物 | |
| KR820001235B1 (ko) | 알킬티오페녹시프로파놀아민의 제조방법 | |
| NO150960B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-(acylamino-aryloksy)-2-hydroksy-3-alkynylaminopropaner | |
| SE443782B (sv) | Vissa nya terapeutiskt aktiva alkyltiofenoxipropanolaminer | |
| JPS62258378A (ja) | チアジアジン−2(3h)−オン誘導体 |